“Medication Chart Review of Potentially Inappropriate Prescribing in E

“Medication Chart Review of Potentially Inappropriate Prescribing in Elderly Inpatients Using Beers Criteria and STOPP/START Criteria” give need for study for this topic

Reading File

Searching PubMed

potentially inappropriate prescribing elderly Beers criteria STOPP START

Searching the Web

need for study potentially inappropriate prescribing elderly inpatients Beers criteria STOPP START criteria medication chart review

Reading Article

Finding Sources

Reading File

Searching PubMed

polypharmacy adverse drug events elderly hospital prevalence

Here is a thorough Need for Study section for the topic "Medication Chart Review of Potentially Inappropriate Prescribing in Elderly Inpatients Using Beers Criteria and STOPP/START Criteria":

Need for Study

1. Global Rise in the Elderly Population and Polypharmacy Burden

The world is experiencing an unprecedented demographic transition. Adults aged 65 years and older now constitute the fastest-growing segment of the global population. This age group is disproportionately affected by multiple chronic conditions - hypertension, diabetes mellitus, heart failure, osteoporosis, cognitive decline - which necessitate the concurrent use of multiple medications (polypharmacy, typically defined as 5 or more drugs). A 2022 systematic review and meta-analysis (PMID: 35854209) confirmed that polypharmacy prevalence is rising steadily across healthcare settings worldwide. With each additional drug, the risk of drug-drug interactions, drug-disease interactions, adverse drug reactions (ADRs), and medication errors compounds exponentially.

2. High Prevalence of Potentially Inappropriate Prescribing (PIP) in the Elderly

Potentially Inappropriate Medications (PIMs) are drugs whose risks outweigh their benefits in older adults due to age-related changes in pharmacokinetics (reduced renal and hepatic clearance, altered volume of distribution) and pharmacodynamics (increased receptor sensitivity). Studies using the Beers and STOPP/START criteria consistently report alarming PIM prevalence rates:

12% to 80% of older adults in community, nursing home, and hospital settings receive at least one PIM (PLOS ONE, 2019).
In a Spanish nursing home study, 48% of residents had at least one PIM by STOPP criteria vs. 25% by Beers criteria (PMC3780483).
In Indian tertiary care settings, STOPP/START identified a significantly higher proportion of PIMs compared to Beers criteria alone (Cureus, 2023).

Despite this documented prevalence, PIP often goes undetected because routine clinical practice lacks a standardized, structured screening process - especially in inpatient settings where prescribing complexity is highest.

3. Serious Clinical Consequences of PIP in Hospitalized Patients

The clinical and economic impact of PIP in elderly inpatients has been extensively documented. A landmark systematic review and meta-analysis of 63 studies (Mekonnen et al., British Journal of Clinical Pharmacology, 2021 - PMID: 34008195) found that PIP in hospitalized older adults is significantly associated with:

91% increased odds of adverse drug event-related hospital admissions
60% increased odds of functional decline
26% increased odds of adverse drug reactions and adverse drug events
Increased risk of falls (consistent across all included studies)

A more recent 2026 meta-analysis (Muzzarelli et al., Int J Clin Pharm - PMID: 40996586) further demonstrated that PIMs identified by STOPP/START criteria were associated with a 1.84-fold increased odds of rehospitalization (95% CI 1.08-3.12). These consequences translate into prolonged hospital stays, increased healthcare costs, reduced quality of life, and preventable mortality.

4. Prescribing Omissions: An Equally Critical but Underrecognized Problem

While much attention is paid to overprescribing, prescribing omissions - failure to prescribe clinically indicated medications - are equally harmful and often overlooked. The START (Screening Tool to Alert doctors to Right Treatment) component of STOPP/START specifically addresses this gap. In the Spanish nursing home study, START identified prescribing omissions in 44% of residents - with the most frequent omissions involving cardiovascular and bone health medications. Without tools like START, these omissions would remain invisible to clinicians conducting informal medication reviews.

5. Limitations of Current Prescribing Practices in Inpatient Settings

The inpatient hospital setting is particularly vulnerable to PIP due to:

Acute illness altering pharmacokinetics/pharmacodynamics, making previously appropriate drugs suddenly harmful
Multiple prescribers across specialties contributing to fragmented prescribing
Medication reconciliation failures during admission and discharge transitions
Time pressure and cognitive overload on clinicians, with no systematic tool for screening all medications simultaneously
Lack of clinical pharmacist integration in many hospitals in low- and middle-income countries

A structured medication chart review using validated criteria at admission and discharge directly addresses these gaps.

6. Superiority and Complementarity of STOPP/START Over Beers Criteria Alone

The Beers Criteria, first published in 1991 and periodically updated by the American Geriatrics Society, is the most widely recognized tool globally. However, it has recognized limitations:

Primarily designed for the North American context; many medications listed are not available or rarely used in other countries
Does not capture prescribing omissions (no equivalent to START)
The STOPP screening tool identified 35% of elderly ED patients with PIMs vs. 25% by Beers, and STOPP-related medications contributed to twice the number of admissions (12% vs. 6%) - as cited in Rosen's Emergency Medicine

STOPP/START version 3 (2023 - PMID: 37256475) has been updated to include a broader physiological systems-based approach, making it more clinically actionable. However, because the two tools detect different subsets of PIP (kappa agreement as low as 0.093 in some studies), using both tools together is recommended for a comprehensive medication review. This complementary use forms the scientific rationale for studies that apply both criteria simultaneously.

7. Gap in Inpatient-Specific, Region-Specific Evidence

While studies on PIP using Beers and STOPP/START criteria exist in community and nursing home settings, there is a relative paucity of inpatient-specific medication chart review studies, particularly from:

Developing countries where prescribing patterns, available medications, disease burden, and healthcare infrastructure differ substantially from Western settings
Tertiary care hospitals where multi-morbid patients are concentrated
Settings with limited clinical pharmacist involvement

A medication chart review in elderly inpatients provides a real-world snapshot of prescribing quality, identifies the most common categories of PIP specific to the local population, and generates data that can inform institutional prescribing policies and clinical pharmacy programs.

8. Potential for Intervention and Improvement

Research consistently shows that medication review using validated criteria, when acted upon, leads to measurable improvement. A 2023 systematic review (PMID: 37582482) found that deprescribing interventions in older patients significantly reduced PIM use and improved clinical outcomes. By identifying the nature and magnitude of PIP at a local level through a chart review study, the groundwork is laid for:

Targeted clinical pharmacist-physician collaborative interventions
Development of institutional prescribing guidelines for elderly patients
Integration of PIM screening tools into electronic health records
Training programs for clinicians on geriatric pharmacology

9. Regulatory and Policy Imperatives

Health systems globally are under increasing pressure to improve medication safety in older adults. The WHO's Medication Without Harm global patient safety challenge (3rd Global Patient Safety Challenge) specifically targets reducing medication-related harm by 50% over 5 years, with elderly patients identified as a high-risk group. Inpatient medication chart review studies using standardized tools directly contribute to this global agenda and provide locally applicable, policy-relevant data.

Summary

In short, a medication chart review using both Beers and STOPP/START criteria in elderly inpatients is needed because:

Rationale	Supporting Evidence
High burden of polypharmacy and PIP in elderly	Prevalence 12-80%; rising global trend
Serious outcomes: ADEs, falls, functional decline, readmission	Meta-analysis: 26-91% increased odds (PMID: 34008195)
Rehospitalization risk with PIMs	OR 1.84 by STOPP/START (PMID: 40996586)
Prescribing omissions equally important	START detects omissions in up to 44% of elderly
STOPP > Beers alone (35% vs 25% detection)	Rosen's Emergency Medicine; PLOS ONE
Tools detect different PIP subsets (kappa 0.093)	Need for combined use
Gap in inpatient/region-specific data	Local evidence needed for policy
Basis for targeted intervention programs	Deprescribing meta-analysis (PMID: 37582482)
WHO patient safety mandate	Medication Without Harm Challenge

This study is therefore timely, necessary, and directly actionable in improving medication safety for one of the most vulnerable patient populations in any healthcare system.

Give in brief

Need for Study (Brief)

The elderly population is growing rapidly, and older adults commonly suffer from multiple chronic diseases requiring several medications simultaneously (polypharmacy). This increases the risk of Potentially Inappropriate Medications (PIMs) - drugs whose risks outweigh benefits in the elderly due to age-related changes in drug metabolism and sensitivity.

Studies report PIM prevalence of 12-80% in hospitalized elderly patients, yet it frequently goes undetected in routine clinical practice. PIP in inpatients is associated with adverse drug reactions, falls, functional decline, and up to 91% increased odds of ADE-related admissions (Mekonnen et al., 2021). PIMs identified by STOPP/START have also been linked to a 1.84-fold increased risk of rehospitalization (Muzzarelli et al., 2026).

The Beers Criteria and STOPP/START Criteria are the two most widely validated tools for detecting PIP. However, they identify different subsets of inappropriate prescribing (agreement as low as kappa = 0.093), meaning neither tool alone is sufficient. Additionally, the START component uniquely detects prescribing omissions - clinically indicated drugs that were never prescribed - found in up to 44% of elderly patients.

Despite this, inpatient-specific medication chart reviews using both tools simultaneously remain limited, particularly in developing countries where prescribing patterns, disease burden, and available medications differ significantly from Western populations.

This study is therefore needed to:

Determine the local prevalence and pattern of PIP in elderly inpatients
Compare the detection ability of Beers vs. STOPP/START criteria
Identify prescribing omissions through START criteria
Generate evidence to guide institutional prescribing policies, clinical pharmacist interventions, and safer prescribing practices for elderly inpatients

Give the link for refered articles

Here are the direct PubMed links for the referenced articles:

Mekonnen et al., 2021 - "Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: A systematic review and meta-analysis." British Journal of Clinical Pharmacology PMID: 34008195 | PMC Full Text
Muzzarelli et al., 2026 - "Association of potentially inappropriate medications with rehospitalisation and death within three months in older patients: a systematic review and meta-analysis." International Journal of Clinical Pharmacy PMID: 40996586 | PMC Full Text
O'Mahony et al., 2023 - "STOPP/START criteria for potentially inappropriate prescribing in older people: version 3." Age and Ageing PMID: 37256475
Gallagher et al. (STOPP/START in Spanish nursing homes) - "Potentially inappropriate prescribing in institutionalised older patients: STOPP-START criteria compared with Beers criteria." PMC Full Text: PMC3780483
Delara et al., 2022 - "Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis." BMC Geriatrics PMID: 35854209
Zhou et al., 2023 - "Deprescribing Interventions for Older Patients: A Systematic Review and Meta-Analysis." Journal of the American Medical Directors Association PMID: 37582482
Comparison of Beers and STOPP/START in Indian elderly (Cureus, 2023) Full PDF - Cureus
WHO Medication Without Harm - 3rd Global Patient Safety Challenge WHO Official Page

This is a shared conversation. Sign in to Orris to start your own chat.